Samuel Achilefu

20.1k total citations · 3 hit papers
337 papers, 14.8k citations indexed

About

Samuel Achilefu is a scholar working on Biomedical Engineering, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Samuel Achilefu has authored 337 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Biomedical Engineering, 110 papers in Molecular Biology and 98 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Samuel Achilefu's work include Nanoplatforms for cancer theranostics (98 papers), Photodynamic Therapy Research Studies (54 papers) and Optical Imaging and Spectroscopy Techniques (50 papers). Samuel Achilefu is often cited by papers focused on Nanoplatforms for cancer theranostics (98 papers), Photodynamic Therapy Research Studies (54 papers) and Optical Imaging and Spectroscopy Techniques (50 papers). Samuel Achilefu collaborates with scholars based in United States, China and France. Samuel Achilefu's co-authors include М. Б. Березин, Walter J. Akers, Yueqing Gu, Gail Sudlow, Sharon Bloch, Hyeran Lee, Baogang Xu, Rui Tang, Yunpeng Ye and Zongren Zhang and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Samuel Achilefu

333 papers receiving 14.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fluorescence Lifetime Measurements and Biological Imaging

2010 1.9k citations М. Б. Березин, Samuel Achilefu profile →
In Vivo Targeted Deep-Tissue Photodynamic Therapy Based on Near-Infrared Light Triggered Upconversion Nanoconstruct

2012 441 citations Yuxiang Ma, Samuel Achilefu et al. profile →
Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases

2023 92 citations Christopher Egbulefu, Samuel Achilefu et al. profile →

Peers

Countries citing papers authored by Samuel Achilefu

Since Specialization

Citations

This map shows the geographic impact of Samuel Achilefu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Achilefu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Achilefu more than expected).

Fields of papers citing papers by Samuel Achilefu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Achilefu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Achilefu. The network helps show where Samuel Achilefu may publish in the future.

Co-authorship network of co-authors of Samuel Achilefu

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Achilefu. A scholar is included among the top collaborators of Samuel Achilefu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Achilefu. Samuel Achilefu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles 2024 ·Theranostics ·(unknown), Lei Fang, (unknown), Julie L. Prior, Brad Manion, Baogang Xu, (unknown), (unknown), (unknown), Rui Tang, Christopher Egbulefu, Monica Shokeen, James D. Quirk, Samuel Achilefu	5
2	Gold nanoparticle-enhanced X-ray microtomography of the rodent reveals region-specific cerebrospinal fluid circulation in the brain 2023 ·Nature Communications ·(unknown), Peter Yang, (unknown), (unknown), Peter O. Bayguinov, Carl D. Hacker, Abraham Z. Snyder, (unknown), (unknown), (unknown), (unknown), (unknown), Sanja Sviben, Samuel Achilefu, Rui Tang, Gabe Haller, James D. Quirk, James A. J. Fitzpatrick, Prabagaran Esakky, Jennifer M. Strahle	16
3	Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting 2023 ·PLoS ONE ·Francesca Fontana, Alison K. Esser, Christopher Egbulefu, Partha Karmakar, Xinming Su, John S. Allen, Yalin Xu, Jennifer L. Davis, (unknown), Jingyu Xiang, Kristin A. Kwakwa, Brad Manion, Suzanne J. Bakewell, Shunqiang Li, Haeseong Park, Gregory M. Lanza, Samuel Achilefu, Katherine N. Weilbaecher	10
4	S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice 2022 ·Blood ·Sena Kim, (unknown), Boram Kim, Julie Ritchey, Kiran Vij, Julie L. Prior, Lynne Marsala, (unknown), Feng Gao, Samuel Achilefu, Matthew Cooper, John F. DiPersio, Jaebok Choi	1
5	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy 2021 ·Leukemia ·Kinan Alhallak, Jennifer Sun, (unknown), (unknown), Julie O’Neal, Barbara Muz, Justin King, Daniel Kohnen, Ravi Vij, Samuel Achilefu, John F. DiPersio, Abdel Kareem Azab	45
6	The membrane-associated form of cyclin D1 enhances cellular invasion 2020 ·Oncogenesis ·Ke Chen, Xuanmao Jiao, Anthony W. Ashton, Agnese Di Rocco, Timothy G. Pestell, Yunguang Sun, Jun Zhao, Mathew C. Casimiro, Zhiping Li, Michael P. Lisanti, Peter A. McCue, Duanwen Shen, Samuel Achilefu, Hallgeir Rui, Richard G. Pestell	21
7	Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance 2019 ·Journal of Nuclear Medicine ·Fijs W. B. van Leeuwen, Margret Schottelius, Oscar R. Brouwer, Sergi Vidal‐Sicart, Samuel Achilefu, Joachim Klode, Hans‐Jürgen Wester, Tessa Buckle	62
8	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease 2018 ·Leukemia ·Jaebok Choi, Matthew Cooper, Karl Staser, (unknown), Kiran Vij, Bing Wang, Lynne Marsala, (unknown), Julie Ritchey, Bader Alahmari, Samuel Achilefu, Ikuo Tsunoda, Mark A. Schroeder, John F. DiPersio	66
9	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma 2017 ·Journal of Controlled Release ·Pilar de la Puente, Micah John Luderer, Cinzia Federico, (unknown), Rebecca C. Gilson, Christopher Egbulefu, Kinan Alhallak, Shruti Shah, Barbara Muz, Jennifer Sun, Justin King, Daniel Kohnen, Noha N. Salama, Samuel Achilefu, Ravi Vij, Abdel Kareem Azab	58
10	Dynamic optical projection of acquired luminescence for aiding oncologic surgery 2013 ·Journal of Biomedical Optics ·Pinaki Sarder, (unknown), Suman Mondal, Gail Sudlow, Samuel Achilefu, Walter J. Akers	12
11	Near-infrared fluorescence goggle system with complementary metal–oxide–semiconductor imaging sensor and see-through display 2013 ·Journal of Biomedical Optics ·Yang Liu, (unknown), Thomas P. Matthews, Walter J. Akers, Gail Sudlow, Suman Mondal, Rui Tang, Viktor Gruev, Samuel Achilefu	45
12	Inhibitory effects of ERβ on proliferation, invasion, and tumor formation of MCF-7 breast cancer cells-prognostication for the use of ERβ-selective therapy 2012 ·Pharmaceutical Biology ·Hui Li, Zhenzhen Tu, (unknown), Zhiyu Qian, Samuel Achilefu, Yueqing Gu	13
13	Dating Bloodstains with Fluorescence Lifetime Measurements 2012 ·Chemistry - A European Journal ·Kevin Guo, Samuel Achilefu, М. Б. Березин	28
14	The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression 2012 ·Molecular and Cellular Biochemistry ·Zhenzhen Tu, Hui Li, Yuxiang Ma, Bin Tang, Junmei Tian, Walter J. Akers, Samuel Achilefu, Yueqing Gu	26
15	Detection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer–based molecular probe 2011 ·Journal of Biomedical Optics ·(unknown), Kevin Guo, Gail Sudlow, М. Б. Березин, Wilson B. Edwards, Samuel Achilefu, Walter J. Akers	30
16	Near-Infrared Fluorescence Lifetime pH-Sensitive Probes 2011 ·Biophysical Journal ·М. Б. Березин, Kevin Guo, Walter J. Akers, (unknown), Joseph P. Culver, (unknown), Olga Vasalatiy, (unknown), Amir Gandjbakhche, Gary L. Griffiths, Samuel Achilefu	48
17	MAb L9E10 to Blood Group H2 Antigen Binds to Colon Cancer Stem Cells and Inhibits Tumor Cell Migration and Invasion 2010 ·Hybridoma ·Ming Xu, Fan Wang, Jeffrey C. Gildersleeve, Samuel Achilefu	5
18	Folate-Polyethylene Glycol Conjugated Near-Infrared Fluorescence Probe with High Targeting Affinity and Sensitivity for In Vivo Early Tumor Diagnosis 2010 ·Molecular Imaging and Biology ·Fei Liu, Dawei Deng, Xinyang Chen, Zhiyu Qian, Samuel Achilefu, Yueqing Gu	59
19	Neutrophil Elastase Mediates Innate Host Protection against Pseudomonas aeruginosa 2008 ·The Journal of Immunology ·Tim O. Hirche, (unknown), Gaëtan Deslée, Sophie C. Gangloff, Samuel Achilefu, Moncef Guenounou, François Lebargy, Robert E. W. Hancock, Azzaq Belaaouaj	84
20	Tumor specific fluorescent contrast agents 2000 ·Proceedings of SPIE - The International Society for Optical Engineering ·Samuel Achilefu, Richard B. Dorshow, Joseph E. Bugaj, Raghavan Rajagopalan	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact